Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578988 | 0.82 | ALDH1A1 (0.57) | HTTHPGDMAPTALDH1A1POLB | |
| SCHEMBL31570917 | 0.79 | KDM4E (0.46) | HPGDMAPTALDH1A1POLBLMNA | |
| SCHEMBL10314578 | 0.79 | ALDH1A1 (0.53) | HTTCYP1A2CYP2C19CYP3A4HPGD | |
| SCHEMBL15920627 | 0.79 | ALDH1A1 (0.51) | HPGDMAPTALDH1A1LMNAKDM4E | |
| SCHEMBL31018139 | 0.78 | ALDH1A1 (0.50) | HTTHPGDMAPTALDH1A1POLB | |
| SCHEMBL8358461 | 0.78 | MAPT (0.65) | HTTCYP2C19HPGDMAPTALDH1A1 | |
| SCHEMBL15876642 | 0.78 | ALDH1A1 (0.50) | HTTHPGDMAPTALDH1A1POLB | |
| SCHEMBL1240163 | 0.78 | ALDH1A1 (0.50) | HTTHPGDMAPTALDH1A1POLB | |
| SCHEMBL8355870 | 0.77 | KMT2A (0.53) | MAPTALDH1A1POLBLMNAKDM4E | |
| SCHEMBL8361597 | 0.77 | KDM4E (0.53) | HTTHPGDMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2723737-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013003383-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013003383-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
| US-5942522-A | 1-BENZYL-3-ETHOXYCARBONYL-4-DIMETHYLAMINOETHOXY-6-METHYL-2-(1H) -QUINOLINONE; ANTIVIRAL AGAINST DNA CONTAINING VIRUSES, SUCH AS HERPES GROUP VIRUSES | SCHERING CORPORATION (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0549729-B1 | ANTIVIRAL COMPOUNDS AND ANTIHYPERTENSIVE COMPOUNDS | SCHERING CORP (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5412104-A | Hypotensive and antiviral agents | SCHERING CORPORATION (US) | 1995-05-02 | — | — | US | disclosed |
| US-5382572-A | Viricides | SCHERING CORPORATION (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0547145-A1 | ANTIVIRAL 2(1H)-QUINOLINONE COMPOUNDS | SCHERING CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992004326-A1 | ANTIVIRAL COMPOUNDS | SCHERING CORPORATION (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | PAICS, SBDS, SORD | HTT 4742/4885CYP1A2 397/4885CYP2C19 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.